Sign In
Buy NUVA
$39.75
+0 (+0%)
At Close: Nov 30, 2023
Globus Medical: NuVasive Merger Unlocks Incremental NOPAT Growth
08:21am, Saturday, 15'th Jun 2024
Globus Medical faced market backlash post-merger with NuVasive, but Q1 FY 2024 showed strong growth and integration efforts. Management revised net sales guidance for FY 2024, aiming for high growth a
Why NuVasive (NUVA) is a Top Growth Stock for the Long-Term
11:17am, Thursday, 31'st Aug 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting
07:00am, Wednesday, 30'th Aug 2023
SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integr
Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600
05:41pm, Monday, 28'th Aug 2023
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insu
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
11:15am, Thursday, 03'rd Aug 2023
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
NuVasive, Inc. (NUVA) Q2 2023 Earnings Call Transcript
08:27pm, Wednesday, 02'nd Aug 2023
NuVasive, Inc. (NASDAQ:NUVA ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Juliet Cunningham – Vice President-Investor Relations Chris Barry – Chief Executive Of
NuVasive (NUVA) Q2 Earnings Meet Estimates
07:28pm, Wednesday, 02'nd Aug 2023
NuVasive (NUVA) came out with quarterly earnings of $0.56 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.47 per share a year ago.
NuVasive Announces Second Quarter 2023 Financial Results
04:05pm, Wednesday, 02'nd Aug 2023
–U.S. Cervical continues to deliver greater than 20% year-over-year growth– –International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO , Aug. 2, 2023 /PRNe
Radcliffe Capital Management, L.P. Acquires Stake in Portage Fintech Acquisition Corp
04:37pm, Thursday, 27'th Jul 2023
Radcliffe Capital Management, L.P. (Trades, Portfolio), a prominent investment firm, recently made a significant acquisition in the stock market.
NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results
07:00am, Monday, 24'th Jul 2023
SAN DIEGO , July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integr
NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
12:57pm, Thursday, 11'th May 2023
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
NuVasive, Inc. (NUVA) Q1 2023 Earnings Call Transcript
10:15pm, Wednesday, 10'th May 2023
NuVasive, Inc. (NASDAQ:NUVA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Chris Barry - Chief Executive Officer
NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
NuVasive (NUVA) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.54 per share a year ago.
Globus Medical: Still Very Attractive After NuVasive Selloff
05:41am, Thursday, 04'th May 2023
Globus Medical caught headlines after announcing the NuVasive merger. Investors have wiped out considerable equity post-announcement, but the worst may be now priced in.
Is NuVasive (NUVA) a Great Value Stock Right Now?
11:25am, Monday, 01'st May 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
